Yarrow Bioscience (YARW) EBT Margin (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly EBT Margin came in at 4168.6% in Q1 2026, up 13290.0% YoY from N/an in Q1 2025, and up 27.46% on a QoQ basis from 5747.0% in Q2 2025.
Yarrow Bioscience (YARW) EBT Margin (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of EBT Margin data on file, last reported at 4168.6% in Q1 2026.
- Quarterly EBT Margin rose 13290.0% year-over-year to 4168.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6384.86% (up 61929.0% YoY) and the FY2025 annual result came in at 4689.82%, up 327078.0% from the prior year.
- EBT Margin rose to 4168.6% in Q1 2026, from 5747.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 4168.6% in Q1 2026 to a low of 26717.24% in Q4 2022.
- A 5-year average of 8164.62% and a median of 5747.0% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin sank 2348647 bps — and 2023, when it surged 1862250 bps.
- Tracing YARW's EBT Margin over 5 years: stood at 26717.24% in 2022, then soared by 70 bps to 8094.74% in 2023, then plunged by 79 bps to 14469.88% in 2024, then jumped by 60 bps to 5747.0% in 2025, then climbed by 27 bps to 4168.6% in 2026.
- The last three EBT Margin figures came in at 4168.6% (Q1 2026), 5747.0% (Q2 2025), and 4301.5% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Yarrow Bioscience | 31.00 Mn | 8.07 Mn | - | -2,899.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,899.00% |
| Mar 31, 2026 | -4,168.60% |
| Jun 30, 2025 | -5,747.00% |
| Mar 31, 2025 | -4,301.50% |
| Dec 31, 2024 | -14,469.88% |
| Sep 30, 2024 | -10,047.11% |
| Jun 30, 2024 | -4,744.95% |
| Mar 31, 2024 | -6,241.00% |
| Dec 31, 2023 | -8,094.74% |
| Sep 30, 2023 | -5,325.44% |
| Jun 30, 2023 | -10,038.00% |
| Mar 31, 2023 | -5,612.00% |
| Dec 31, 2022 | -26,717.24% |
| Sep 30, 2022 | -5,541.92% |
| Jun 30, 2022 | -6,535.71% |
| Mar 31, 2022 | -4,884.27% |
| Dec 31, 2021 | -3,230.77% |
| Sep 30, 2021 | -10,733.83% |
| Jun 30, 2021 | -3,622.03% |
| Mar 31, 2021 | -4,728.70% |